US1009390A
(en)
|
1910-04-18 |
1911-11-21 |
Miehle Printing Press & Mfg |
Manufacture of printing-plates.
|
US1035847A
(en)
|
1910-05-23 |
1912-08-20 |
William P Bettendorf |
Means for cushioning the bodies of railway-cars.
|
US1020828A
(en)
|
1911-12-11 |
1912-03-19 |
William A Rees |
Electric washing-machine.
|
US1044284A
(en)
|
1912-04-29 |
1912-11-12 |
Gen Electric |
Heating device.
|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US5906936A
(en)
*
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
AU675916B2
(en)
|
1991-06-14 |
1997-02-27 |
Genentech Inc. |
Method for making humanized antibodies
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
DE69233204T2
(de)
|
1991-12-13 |
2004-07-15 |
Xoma Corp., Berkeley |
Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
WO1993019163A1
(en)
|
1992-03-18 |
1993-09-30 |
Yeda Research And Development Co, Ltd. |
Chimeric receptor genes and cells transformed therewith
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
ATE401348T1
(de)
|
1999-05-27 |
2008-08-15 |
Us Gov Health & Human Serv |
Immunokonjugate mit hoher bindungsaffinität
|
AU5622700A
(en)
|
1999-06-16 |
2001-01-02 |
Myelos Corporation |
Retro-inverso peptides derived from leukemia inhibitory factor
|
WO2001029058A1
(en)
|
1999-10-15 |
2001-04-26 |
University Of Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
IL151287A0
(en)
|
2000-02-24 |
2003-04-10 |
Xcyte Therapies Inc |
A method for stimulation and concentrating cells
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
WO2002002621A2
(en)
|
2000-06-30 |
2002-01-10 |
Zymogenetics, Inc. |
Mammalian secreted proteins
|
JP5312721B2
(ja)
|
2000-11-07 |
2013-10-09 |
シティ・オブ・ホープ |
Cd19特異的再指向免疫細胞
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
EP1433793A4
(en)
|
2001-09-13 |
2006-01-25 |
Inst Antibodies Co Ltd |
METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
|
WO2003068822A2
(en)
|
2002-02-13 |
2003-08-21 |
Micromet Ag |
De-immunized (poly)peptide constructs
|
DE10244457A1
(de)
|
2002-09-24 |
2004-04-01 |
Johannes-Gutenberg-Universität Mainz |
Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
|
CA2505326A1
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
US7251470B2
(en)
|
2003-06-25 |
2007-07-31 |
Nokia Corporation |
Emergency response system with personal emergency device
|
KR20060041205A
(ko)
|
2003-07-01 |
2006-05-11 |
이뮤노메딕스, 인코오포레이티드 |
양특이성 항체들의 다가 담체들
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
US20050048617A1
(en)
|
2003-08-18 |
2005-03-03 |
Medimmune, Inc. |
Humanization of antibodies
|
JP2007528723A
(ja)
|
2003-08-22 |
2007-10-18 |
メディミューン,インコーポレーテッド |
抗体のヒト化
|
KR101229731B1
(ko)
|
2003-10-16 |
2013-03-07 |
암젠 리서치 (뮌헨) 게엠베하 |
다중특이적 탈면역화된 cd3-바인더
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
JP4813364B2
(ja)
|
2003-11-25 |
2011-11-09 |
アメリカ合衆国 |
突然変異型抗cd22抗体および免疫複合体
|
US20050238626A1
(en)
|
2004-04-01 |
2005-10-27 |
Lili Yang |
Antigen specific T cell therapy
|
WO2006020258A2
(en)
|
2004-07-17 |
2006-02-23 |
Imclone Systems Incorporated |
Novel tetravalent bispecific antibody
|
WO2006018833A2
(en)
|
2004-08-16 |
2006-02-23 |
Tadiran Spectralink Ltd. |
A wearable device, system and method for measuring a pulse while a user is in motion
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
WO2006099141A2
(en)
|
2005-03-10 |
2006-09-21 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
US20090047211A1
(en)
|
2005-05-12 |
2009-02-19 |
The Govt. Of The U.S. As Represented By The Sec. Of The Dept. Of Health And Human Services |
Anti-mesothelin antibodies useful for immunological assays
|
WO2007024715A2
(en)
|
2005-08-19 |
2007-03-01 |
Abbott Laboratories |
Dual variable domain immunoglobin and uses thereof
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
EP2856876B1
(en)
|
2007-03-30 |
2018-01-31 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
GB0721686D0
(en)
|
2007-11-05 |
2007-12-12 |
Medinnova As |
Polypeptides
|
DK2215121T3
(en)
|
2007-11-26 |
2016-05-02 |
Bayer Ip Gmbh |
ANTI-mesothelin ANTIBODIES AND USES THEREOF
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
KR20090092900A
(ko)
|
2008-02-28 |
2009-09-02 |
신준호 |
어린이 및 노약자 안전보호시스템
|
US20090322513A1
(en)
|
2008-06-27 |
2009-12-31 |
Franklin Dun-Jen Hwang |
Medical emergency alert system and method
|
WO2010025177A1
(en)
|
2008-08-26 |
2010-03-04 |
City Of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
EP2342228B1
(en)
|
2008-09-12 |
2017-09-06 |
Oxford University Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
BRPI0919840B1
(pt)
|
2008-10-01 |
2023-02-28 |
Amgen Research (Munich) Gmbh |
Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
|
WO2010052014A1
(en)
*
|
2008-11-07 |
2010-05-14 |
Micromet Ag |
Treatment of acute lymphoblastic leukemia
|
BRPI1005984A2
(pt)
|
2009-02-23 |
2016-10-04 |
Glenmark Pharmaceuticals Sa |
anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
|
LT2406284T
(lt)
*
|
2009-03-10 |
2016-10-10 |
Biogen Ma Inc. |
Antikūnai prieš b ląstelių subrendimo antigenus
|
EP2421899B1
(en)
|
2009-04-23 |
2016-06-08 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-human ror1 antibodies
|
EP2258719A1
(en)
*
|
2009-05-19 |
2010-12-08 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Multiple target T cell receptor
|
ES2649890T3
(es)
|
2009-10-23 |
2018-01-16 |
Nexisvision, Inc. |
Enervación corneal para el tratamiento de dolor ocular
|
US9181527B2
(en)
|
2009-10-29 |
2015-11-10 |
The Trustees Of Dartmouth College |
T cell receptor-deficient T cell compositions
|
PT2361936T
(pt)
|
2010-02-25 |
2016-07-15 |
Affimed Gmbh |
Molécula que se liga a antigénio e utilizações desta
|
PT2552959T
(pt)
|
2010-03-26 |
2017-04-21 |
Memorial Sloan Kettering Cancer Center |
Anticorpos para muc16 e métodos de utilização dos mesmos
|
US10357577B2
(en)
|
2010-07-16 |
2019-07-23 |
Auckland Uniservices Limited |
Bacterial nitroreductase enzymes and methods relating thereto
|
EP2614143B1
(en)
|
2010-09-08 |
2018-11-07 |
Baylor College Of Medicine |
Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
|
US20130323214A1
(en)
|
2010-10-27 |
2013-12-05 |
Stephen M.G. Gottschalk |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
EP2632954B2
(en)
|
2010-10-27 |
2021-07-07 |
Amgen Research (Munich) GmbH |
Means and methods for treating dlbcl
|
CA2818992C
(en)
|
2010-12-01 |
2021-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric rabbit/human ror1 antibodies
|
SG190997A1
(en)
|
2010-12-09 |
2013-07-31 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
KR20140014116A
(ko)
|
2010-12-20 |
2014-02-05 |
제넨테크, 인크. |
항-메소텔린 항체 및 면역접합체
|
ES2634098T3
(es)
|
2011-01-14 |
2017-09-26 |
The Regents Of The University Of California |
Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos.
|
US9402865B2
(en)
|
2011-01-18 |
2016-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cancer
|
ES2588730T3
(es)
|
2011-03-17 |
2016-11-04 |
Miltenyi Biotec Gmbh |
Preparados celulares agotados en lo que respecta a TCRalfa/beta
|
US9266960B2
(en)
|
2011-04-08 |
2016-02-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
|
SG11201400527XA
(en)
|
2011-09-16 |
2014-04-28 |
Univ Pennsylvania |
Rna engineered t cells for the treatment of cancer
|
KR101471647B1
(ko)
|
2011-10-26 |
2014-12-11 |
국립암센터 |
변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물
|
WO2013063419A2
(en)
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
WO2013067492A1
(en)
|
2011-11-03 |
2013-05-10 |
The Trustees Of The University Of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
AR089114A1
(es)
|
2011-12-09 |
2014-07-30 |
Amgen Res Munich Gmbh |
PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
|
AU2013221672B2
(en)
|
2012-02-13 |
2017-11-09 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
SG11201404285VA
(en)
|
2012-02-22 |
2014-10-30 |
Univ Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
SG11201404284SA
(en)
|
2012-02-22 |
2014-10-30 |
Univ Pennsylvania |
Use of the cd2 signaling domain in second-generation chimeric antigen receptors
|
CA3209571A1
(en)
|
2012-03-23 |
2013-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
CN104379179A
(zh)
|
2012-04-11 |
2015-02-25 |
美国卫生和人力服务部 |
靶向b-细胞成熟抗原的嵌合抗原受体
|
US20130280220A1
(en)
|
2012-04-20 |
2013-10-24 |
Nabil Ahmed |
Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
|
US9127081B2
(en)
|
2012-05-10 |
2015-09-08 |
Washington University |
Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
|
MX370265B
(es)
|
2012-05-25 |
2019-12-09 |
Cellectis |
Métodos para manipular por ingeniería genética célula t alogénica y resistente a inmunosupresores para inmunoterapia.
|
EP2872617A4
(en)
|
2012-07-13 |
2015-12-09 |
Univ Pennsylvania |
EXTENSION OF EPITOPES IN RELATION TO T CAR LYMPHOCYTES
|
EP3730512A1
(en)
|
2012-07-13 |
2020-10-28 |
The Trustees of the University of Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
EP2872533B1
(en)
|
2012-07-13 |
2019-04-24 |
The Trustees Of The University Of Pennsylvania |
Methods of assessing the suitability of transduced t cells for administration
|
SG11201501259QA
(en)
|
2012-08-20 |
2015-03-30 |
Hutchinson Fred Cancer Res |
Method and compositions for cellular immunotherapy
|
AU2013324049B2
(en)
|
2012-09-27 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
EP2904106A4
(en)
|
2012-10-01 |
2016-05-11 |
Univ Pennsylvania |
COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER
|
RU2020124583A
(ru)
|
2012-10-02 |
2020-08-03 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Композиции и способы для иммунотерапии
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
JP6571527B2
(ja)
|
2012-11-21 |
2019-09-04 |
ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドWuhan Yzy Biopharma Co., Ltd. |
二重特異性抗体
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
WO2014099671A1
(en)
|
2012-12-20 |
2014-06-26 |
Bluebird Bio, Inc. |
Chimeric antigen receptors and immune cells targeting b cell malignancies
|
WO2014122144A1
(en)
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
|
CA3115383A1
(en)
|
2013-02-06 |
2014-08-14 |
Celgene Corporation |
Modified t lymphocytes having improved specificity
|
EP3881868B1
(en)
|
2013-02-15 |
2023-09-27 |
The Regents Of The University Of California |
Chimeric antigen receptor and methods of use thereof
|
US9573988B2
(en)
*
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
CN113699114A
(zh)
|
2013-02-26 |
2021-11-26 |
纪念斯隆-凯特琳癌症中心 |
用于免疫疗法的组合物和方法
|
CN105143270B
(zh)
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
WO2014134412A1
(en)
|
2013-03-01 |
2014-09-04 |
Regents Of The University Of Minnesota |
Talen-based gene correction
|
WO2014138306A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
IL300508A
(en)
|
2013-03-15 |
2023-04-01 |
Memorial Sloan Kettering Cancer Center |
Preparations and methods for immunotherapy
|
CN111643663A
(zh)
|
2013-03-15 |
2020-09-11 |
细胞基因公司 |
修饰的t淋巴细胞
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
PT2981607T
(pt)
|
2013-04-03 |
2020-11-20 |
Memorial Sloan Kettering Cancer Center |
Geração eficaz de células t direcionadas a tumores, derivadas de células estaminais pluripotentes
|
FI2997141T3
(fi)
|
2013-05-13 |
2022-12-15 |
|
CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
|
US11311575B2
(en)
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
AU2014268364A1
(en)
|
2013-05-24 |
2015-12-10 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
ES2645393T3
(es)
|
2013-05-29 |
2017-12-05 |
Cellectis |
Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
US20160355588A1
(en)
|
2013-07-12 |
2016-12-08 |
Zymeworks Inc. |
Bispecific CD3 and CD19 Antigen Binding Constructs
|
CA2954168C
(en)
|
2013-08-02 |
2023-09-19 |
The Regents Of The University Of California |
Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
|
US20150087810A1
(en)
|
2013-09-25 |
2015-03-26 |
Cytomx Therapeutics, Inc. |
Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
|
GB201317929D0
(en)
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
EP3057994B1
(en)
|
2013-10-15 |
2020-09-23 |
The Scripps Research Institute |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
CA2926698C
(en)
|
2013-10-15 |
2021-06-22 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
EP3083691A2
(en)
|
2013-12-20 |
2016-10-26 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
KR20230007559A
(ko)
|
2013-12-20 |
2023-01-12 |
프레드 허친슨 캔서 센터 |
태그된 키메라 이펙터 분자 및 그의 리셉터
|
CN106459182B
(zh)
|
2013-12-30 |
2021-09-03 |
岸迈生物科技有限公司 |
串联fab免疫球蛋白及其用途
|
JP2017507917A
(ja)
|
2014-01-14 |
2017-03-23 |
セレクティスCellectis |
軟骨魚類由来の抗原認識ドメインを使用したキメラ抗原受容体
|
US11028143B2
(en)
*
|
2014-01-21 |
2021-06-08 |
Novartis Ag |
Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
CA2936984A1
(en)
|
2014-01-24 |
2015-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors
|
US20150344844A1
(en)
|
2014-02-04 |
2015-12-03 |
Marc Better |
Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
|
EP3505623A1
(en)
|
2014-02-14 |
2019-07-03 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
EP3105335B1
(en)
|
2014-02-14 |
2019-10-02 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
AU2015220762B2
(en)
|
2014-02-21 |
2019-05-02 |
Cellectis |
Method for in situ inhibition of regulatory T cells
|
EP3110445A4
(en)
|
2014-02-25 |
2017-09-27 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
EP3119425B1
(en)
|
2014-03-15 |
2020-09-23 |
Novartis AG |
Regulatable chimeric antigen receptor
|
JP6726656B2
(ja)
|
2014-04-01 |
2020-07-22 |
バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハーBiontech Cell & Gene Therapies Gmbh |
クローディン6特異的免疫受容体およびt細胞エピトープ
|
CA2945620C
(en)
|
2014-04-14 |
2022-12-06 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
MX2016013964A
(es)
|
2014-04-25 |
2017-04-06 |
Bluebird Bio Inc |
Receptores de antigenos quimericos del promotor mnd.
|
BR112016024957A2
(pt)
|
2014-04-25 |
2017-10-24 |
Bluebird Bio Inc |
métodos aperfeiçoados para fabricação de terapias celulares adotivas
|
CA2984484C
(en)
|
2014-05-02 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor t cells
|
US10287360B2
(en)
|
2014-05-23 |
2019-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Anti-EGFR conformational single domain antibodies and uses thereof
|
US11041021B2
(en)
|
2014-05-23 |
2021-06-22 |
University Of Florida Research Foundation, Incorporated |
Car based immunotherapy
|
CN107106665A
(zh)
|
2014-06-06 |
2017-08-29 |
纪念斯隆-凯特琳癌症中心 |
靶向间皮素的嵌合抗原受体及其用途
|
KR20170032406A
(ko)
|
2014-07-15 |
2017-03-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 조작된 세포
|
JP7054622B2
(ja)
|
2014-07-21 |
2022-04-14 |
ノバルティス アーゲー |
ヒト化抗bcmaキメラ抗原受容体を使用した癌の処置
|
US20170226216A1
(en)
|
2014-07-24 |
2017-08-10 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
DK3453406T3
(da)
|
2014-07-29 |
2021-07-12 |
Cellectis |
ROR1(NTRKR1)-specifikke kimære antigenreceptorer til cancerimmunterapi
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
US9994817B2
(en)
|
2014-08-07 |
2018-06-12 |
Northwestern University |
Use of ligands for the programmed cell death receptor conjugated to solid supports for cultivating human regulatory T cells
|
US9546206B2
(en)
|
2014-08-08 |
2017-01-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity PD-1 agents and methods of use
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
US20180080008A1
(en)
|
2014-08-12 |
2018-03-22 |
Anthrogenesis Corporation |
Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
|
ES2913865T3
(es)
|
2014-08-28 |
2022-06-06 |
Bioatla Inc |
Receptores de antígeno quimérico condicionalmente activos para células T modificadas
|
GB201415347D0
(en)
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
SG10201902168PA
(en)
|
2014-09-09 |
2019-04-29 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
KR102683584B1
(ko)
|
2014-09-19 |
2024-07-10 |
시티 오브 호프 |
IL13Rα2를 표적화하는 공자극 키메라 항원 수용체 T 세포
|
WO2016054520A2
(en)
*
|
2014-10-03 |
2016-04-07 |
The California Institute For Biomedical Research |
Engineered cell surface proteins and uses thereof
|
MX2017004603A
(es)
|
2014-10-07 |
2017-06-30 |
Cellectis |
Metodo para modular actividad de celulas inmunes inducidas por car.
|
CN107106610A
(zh)
|
2014-10-20 |
2017-08-29 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗中的给药的组合物和方法
|
KR20170074243A
(ko)
†
|
2014-10-31 |
2017-06-29 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
변형된 t 세포의 생성 방법 및 조성물
|
WO2016073381A1
(en)
|
2014-11-03 |
2016-05-12 |
Cerus Corporation |
Compositions and methods for improved car-t cell therapies
|
KR20240023204A
(ko)
|
2014-11-05 |
2024-02-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
형질도입 및 세포 프로세싱을 위한 방법
|
ES2808853T3
(es)
|
2014-11-20 |
2021-03-02 |
Hoffmann La Roche |
Cadenas ligeras comunes y procedimientos de uso
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
ES2692206T3
(es)
|
2014-11-26 |
2018-11-30 |
Miltenyi Biotec Gmbh |
Inmunoterapia combinada de receptores de reconocimiento de antígenos y células hematopoyéticas para el tratamiento de enfermedades
|
EP3029067A1
(en)
|
2014-12-01 |
2016-06-08 |
Deutsches Krebsforschungszentrum |
Use of blocking-reagents for reducing unspecific T cell-activation
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
ES2819553T3
(es)
|
2014-12-03 |
2021-04-16 |
Juno Therapeutics Inc |
Métodos y composiciones para terapia celular adoptiva
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
CN107208047B
(zh)
|
2014-12-05 |
2021-09-21 |
纪念斯隆-凯特琳癌症中心 |
靶向b-细胞成熟抗原的嵌合抗原受体及其用途
|
ES2899779T3
(es)
|
2014-12-05 |
2022-03-14 |
Memorial Sloan Kettering Cancer Center |
Receptores antigénicos quiméricos dirigidos a receptor acoplado a proteína G y usos de los mismos
|
SG11201704548PA
(en)
|
2014-12-05 |
2017-07-28 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting b-cell maturation antigen and methods of use
|
EP3233095A2
(en)
|
2014-12-17 |
2017-10-25 |
Cellectis |
INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
|
EP3037170A1
(en)
|
2014-12-27 |
2016-06-29 |
Miltenyi Biotec GmbH |
Multisort cell separation method
|
CA3197849A1
(en)
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
JP2018503399A
(ja)
|
2015-01-14 |
2018-02-08 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
多特異性免疫調節抗原結合構築物
|
EP3245231B1
(en)
|
2015-01-16 |
2020-08-12 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
GB201501175D0
(en)
|
2015-01-23 |
2015-03-11 |
Univ Oslo Hf |
A universal T-cell for personalised medicine
|
CN107835820B
(zh)
|
2015-01-26 |
2021-10-15 |
芝加哥大学 |
识别癌症特异性IL13Rα2的CAR T细胞
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
EP3253414A4
(en)
|
2015-02-05 |
2018-07-11 |
The University Of Queensland |
Targeting constructs for delivery of payloads
|
CN107635578A
(zh)
|
2015-02-05 |
2018-01-26 |
Stc.Unm 公司 |
抗前‑bcr拮抗剂和方法
|
US20160228547A1
(en)
|
2015-02-06 |
2016-08-11 |
Batu Biologics, Inc. |
Chimeric antigen receptor targeting of tumor endothelium
|
US10647778B2
(en)
|
2015-02-09 |
2020-05-12 |
University Of Florida Research Foundation, Incorporated |
Bi-specific chimeric antigen receptor and uses thereof
|
WO2016127257A1
(en)
|
2015-02-12 |
2016-08-18 |
University Health Network |
Chimeric antigen receptors
|
US20160237407A1
(en)
|
2015-02-17 |
2016-08-18 |
Batu Biologics, Inc. |
Universal donor chimeric antigen receptor cells
|
IL284985B2
(en)
|
2015-02-18 |
2023-03-01 |
Enlivex Therapeutics R& D Ltd |
Combined immunotherapy and cytokine control therapy for cancer treatment
|
US10590182B2
(en)
|
2015-02-24 |
2020-03-17 |
The Regents Of The University Of California |
Binding-triggered transcriptional switches and methods of use thereof
|
JP6336684B2
(ja)
|
2015-03-02 |
2018-06-06 |
イノベイティブ セルラー セラピューティクス シーオー.,エルティディ.Innovative Cellular Therapeutics Co.,Ltd. |
Pd−l1によって誘導される免疫寛容の低減
|
KR20170120701A
(ko)
|
2015-03-05 |
2017-10-31 |
프레드 헛친슨 켄서 리서치 센터 |
면역조절 융합 단백질 및 그 용도
|
GB201504840D0
(en)
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
KR20170134525A
(ko)
|
2015-04-02 |
2017-12-06 |
메모리얼 슬로안-케터링 캔서 센터 |
Tnfrsf14 / hvem 단백질 및 이의 이용 방법
|
CN114634943A
(zh)
|
2015-05-18 |
2022-06-17 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
WO2016203048A1
(en)
|
2015-06-19 |
2016-12-22 |
Kobold Sebastian |
Pd-1-cd28 fusion proteins and their use in medicine
|
EP3313883B1
(en)
|
2015-06-23 |
2023-12-06 |
Memorial Sloan Kettering Cancer Center |
Novel pd-1 immune modulating agents
|
KR20180038447A
(ko)
|
2015-06-29 |
2018-04-16 |
더 존스 홉킨스 유니버시티 |
면역 체크포인트 키메라 수용체 치료법
|
US11242375B2
(en)
|
2015-09-04 |
2022-02-08 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
CN106519037B
(zh)
|
2015-09-11 |
2019-07-23 |
科济生物医药(上海)有限公司 |
可活化的嵌合受体
|
AU2016333898B2
(en)
|
2015-10-05 |
2020-11-12 |
Precision Biosciences, Inc. |
Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
|
US11421013B2
(en)
|
2015-10-23 |
2022-08-23 |
Eureka Therapeutics, Inc. |
Antibody/T-cell receptor chimeric constructs and uses thereof
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
CN105331585A
(zh)
|
2015-11-13 |
2016-02-17 |
科济生物医药(上海)有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
CN109072194B
(zh)
|
2015-12-09 |
2022-12-27 |
纪念斯隆-凯特林癌症中心 |
免疫细胞组合物及其使用方法
|
CN109069597A
(zh)
|
2015-12-22 |
2018-12-21 |
诺华股份有限公司 |
间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
|
US20170224837A1
(en)
|
2016-02-10 |
2017-08-10 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
PT3433280T
(pt)
|
2016-03-22 |
2023-06-15 |
Hoffmann La Roche |
Moléculas biespecíficas das células t ativadas pela protease
|
EP3433269B1
(en)
|
2016-03-23 |
2023-09-27 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Fusion proteins of pd-1 and 4-1bb
|
EA201891965A1
(ru)
|
2016-04-01 |
2019-04-30 |
Кайт Фарма, Инк. |
Химерные рецепторы антигенов и т-клеточные рецепторы и способы их применения
|
FI3468997T3
(fi)
|
2016-06-08 |
2023-10-31 |
Xencor Inc |
Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
WO2018044866A1
(en)
|
2016-08-30 |
2018-03-08 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use for treating viral and other infections
|
WO2018067993A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
|
CA3047999A1
(en)
|
2016-12-21 |
2018-06-28 |
TCR2 Therapeutics Inc. |
Engineered t cells for the treatment of cancer
|
WO2018119198A1
(en)
|
2016-12-22 |
2018-06-28 |
Windmil Therapeutics, Inc. |
Compositions and methods for modulating the immune system
|
CN108341872B
(zh)
|
2017-01-23 |
2020-05-19 |
科济生物医药(上海)有限公司 |
靶向bcma的抗体及其应用
|
AU2018251150B2
(en)
|
2017-04-13 |
2024-05-09 |
Albert-Ludwigs-Universität Freiburg |
New sequence specific reagents targeting CCR5 in primary hematopoietic cells
|
CN110741016A
(zh)
|
2017-04-26 |
2020-01-31 |
优瑞科生物技术公司 |
嵌合抗体/t-细胞受体构筑体及其用途
|
WO2018232020A1
(en)
|
2017-06-13 |
2018-12-20 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
SG11202002321YA
(en)
|
2017-09-27 |
2020-04-29 |
Univ Southern California |
Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
|
GB201800298D0
(en)
|
2018-01-09 |
2018-02-21 |
Autolus Ltd |
Method
|
MX2020008184A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70.
|
EP3765039A4
(en)
|
2018-03-09 |
2021-12-08 |
TCR2 Therapeutics Inc. |
COMPOSITIONS AND METHODS FOR REPROGRAMMING TCR USING FUSION PROTEINS
|
WO2019222275A2
(en)
|
2018-05-14 |
2019-11-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using inducible fusion proteins
|
KR20210049816A
(ko)
|
2018-07-26 |
2021-05-06 |
티씨알2 테라퓨틱스 인크. |
표적 특이적 융합 단백질을 사용하는 tcr 리프로그래밍을 위한 조성물 및 방법
|
WO2020043152A1
(en)
|
2018-08-29 |
2020-03-05 |
Nanjing Legend Biotech Co., Ltd. |
Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
|
EP3844192A1
(en)
|
2018-08-30 |
2021-07-07 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
CN114206357A
(zh)
|
2019-03-22 |
2022-03-18 |
T细胞受体治疗公司 |
使用融合蛋白进行tcr重编程的组合物和方法
|
WO2020219563A1
(en)
|
2019-04-22 |
2020-10-29 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US20210130438A1
(en)
|
2019-10-28 |
2021-05-06 |
The Broad Institute, Inc. |
Pan-cancer t cell exhaustion genes
|
AU2021205501A1
(en)
|
2020-01-10 |
2022-08-18 |
TCR2 Therapeutics Inc. |
Compositions and methods for autoimmunity regulation
|
WO2021155034A1
(en)
|
2020-01-29 |
2021-08-05 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using muc16 specific fusion proteins
|
EP4146233A4
(en)
|
2020-05-05 |
2024-05-22 |
TCR2 Therapeutics Inc. |
COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING WITH CD70-SPECIFIC FUSION PROTEINS
|
WO2022020720A1
(en)
|
2020-07-24 |
2022-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for treating cancer
|
WO2022056321A1
(en)
|
2020-09-10 |
2022-03-17 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using gpc3 specific fusion proteins
|
WO2022177966A1
(en)
|
2021-02-16 |
2022-08-25 |
TCR2 Therapeutics Inc. |
Compositions and methods for the treatment of hiv
|
US20230065936A1
(en)
|
2021-04-09 |
2023-03-02 |
Tcr2 Therapeutics Inc |
Compositions and methods for treating cancer
|
WO2023044039A1
(en)
|
2021-09-16 |
2023-03-23 |
TCR2 Therapeutics Inc. |
Compositions and methods for treating cancer
|